Please assess the completion status of the following clinical trial:

Trial Title: Cohort Event Monitoring Study of Pyramax®

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Uncomplicated malaria (Plasmodia of any species) diagnosed as per national policies and in line with WHO recommendations:~  * Fever or history of fever in the previous 24 h and/or the presence of anaemia, for which pallor of the palms appears to be the most reliable sign in young children.~ * Confirmation of malaria by a parasitological diagnosis (RDT or Microscopy (thick blood smear). analysis).~* Weight ≥5 kg - \< 20 kg (granules); ≥20 kg (tablets).~* Ability to take an oral medication.~* Ability and willingness to participate based on signed informed consent (a parent or a guardian has to sign for children below 18 years old) and on signed assent form for minors that could be required per national regulations in each participating country.~* The patient has to comply with all scheduled follow-up visits.~Exclusion Criteria:~* Patients with clinical signs or symptoms of hepatic injury (such as nausea, abdominal pain associated with jaundice) or known severe liver disease (i.e. decompensated cirrhosis, Child-Pugh stage 3 or 4).~* Known allergy to artemisinin and/or to pyronaridine.~* Known pregnancy.~* Lactating women should be excluded if other anti-malarial treatments are available.~* Complicated malaria as per WHO definition (Annex 2)~* Patients that the investigator considers would be at particular risk if receiving an anti-malarial or if participating in the study.~* Patients having been treated with Pyramax in the previous 28 days.

- Gender: ALL
- Minimum Age: 3 Months
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pyramax (Type: EXPERIMENTAL): Pyronaridine artesunate tablets (180/60mg) and granules (60/20mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).